Dear Ms Micklewright
Thank you for your email and apologies for the delay in getting back to you. I now provide the text of your Freedom of Information response below.
Kind regards
Elisabeth Hecker
Freedom of Information Officer
Sussex Partnership NHS Foundation Trust
Trust HQ | Swandean | Arundel Road | BN13 3EP
Email: FOI@spft.nhs.uk
Please provide Electro Convulsive Treatment (ECT) information under the FOI act to the following questions: -
1.Please supply patient’s information ECT leaflet - attached
2.Please supply patient ECT consent form - attached
3.Please supply any ECT reports/investigations
None.
4.How many ECT in 2023?
82 courses, including acute and continuation.
5.What proportion of patients were men/women?
45 acute female, 23 acute male, <5* non-binary.
6.How old were they?
Age range 29-92, mean age 68.
7.What proportion of patients were classified people of the global majority or racialised communities ("POC / BAME")?
None
8.How many people covered by the equality act received ECT?
All our patients who receive treatment have characteristics protected by the Equalities Act.
9.How many people were offered talking therapy prior to ECT?
All patients for whom talking therapy is indicated are offered this prior to receiving ECT.
10.How many were receiving ECT for the first time?
38
11.How many patients consented to ECT?
52
12.How many ECT complaints were investigated outside the NHS and CCG?
None.
13.How many patients died during or 1 month after ECT and what was the cause (whether or not ECT was considered the cause)?
We cannot give details of individual cases due to confidentiality.
14.How many patients died within 6 months after ECT and what was the cause (whether or not ECT was considered the cause)?
We cannot give details of individual cases due to confidentiality.
15.How many patients died by suicide within 6 months of receiving ECT (whether or not ECT was considered the cause)?
We do not collect this data specifically in relation to patients who have received a specific treatment.
16.How many patients have suffered complications during and after ECT and what were those complications?
We cannot give details on individual cases due to confidentiality.
17.Have there been any formal complaints from patients/relatives about ECT?
No.
18.If so, what was their concerns?
N/A
19.How many patients report memory loss/loss of cognitive function?
Memory function is routinely assessed, objectively and subjectively, before ECT and after each treatment. Our data show improvement in memory, during a course of ECT, using each measure.
20.What tests are used to assess memory loss/loss of cognitive function?
Montreal Cognitive Assessment or Mini-Mental State Examination (objective) - CPRS item 17 (subjective).
21.Have MRI or CT scans been used before and after ECT?
Yes.
22.If so, what was the conclusion?
We cannot give details on individual cases due to confidentiality.
23.How does the Trust plan to prevent ECT in the future?
There are no plans to prevent ECT, as it is a well-researched successful treatment, only to continue to administer it with informed consent or within the legal framework of the Mental Health Act once other treatment methods have failed.
Please provide restraints information under the FOI act to the following questions: -
1.Please supply any Restraints/investigations
2.How many RESTRAINTS in 2023?
|
Restraint Incidents 2023 |
|
1240 |
3.What proportion of patients were men/women?
|
Male (Including Trans Man) |
Female (Including Trans Woman) |
Not Known |
Not Specified |
|
353 |
858 |
0 |
29 |
4.How old were they?
|
Age group |
No. Patients |
|
0-17 |
155 |
|
18-30 |
581 |
|
31-40 |
223 |
|
41-50 |
98 |
|
51-60 |
89 |
|
61-70 |
62 |
|
71 And Over |
32 |
5.What proportion of patients were classified people of the global majority or racialised communities ("POC / BAME")?
|
Ethnicity |
No. Patients |
|
Asian or Asian British - Any other Asian background |
11 |
|
Asian or Asian British - Bangladeshi |
<5* |
|
Asian or Asian British - Indian |
<5* |
|
Asian or Asian British - Pakistani |
<5* |
|
Black or Black British - African |
44 |
|
Black or Black British - Any other Black background |
<5* |
|
Black or Black British - Caribbean |
5 |
|
Mixed - Any other mixed background |
7 |
|
Mixed - White and Asian |
<5* |
|
Mixed - White And Black African |
<5* |
|
Mixed - White and Black Caribbean |
5 |
|
Not Known |
47 |
|
Not Stated |
139 |
|
Other Ethnic Groups - Any other ethnic group |
27 |
|
Other Ethnic Groups - Arab |
8 |
|
Other Ethnic Groups - Chinese |
6 |
|
White |
17 |
|
White - Any other White background |
43 |
|
White - British |
872 |
6.How many people covered by the equality act were restrained? All our patients who receive treatment have characteristics protected by the Equalities Act.
7.How many RESTRAINTS were investigated outside the NHS and CCG? - Nil
8.How many patients died during or 1 month after RESTRAINTS and what was the cause (whether or not RESTRAINTS was considered the cause)? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
9.How many patients died within 6 months after RESTRAINTS and what was the cause (whether or not RESTRAINTS was considered the cause)? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
10.How many patients died by suicide within 6 months of receiving RESTRAINTS (whether or not RESTRAINTS was considered the cause)? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
11.How many patients have suffered complications during and after RESTRAINTS and what were those complications? - <5
12.Have there been any formal complaints from patients/relatives about RESTRAINTS? - <5
13.If so, what was their concerns? This is not a valid FOI question
14.Are counts of forced injections available? This is not a term used in the Trust
15.How does the Trust plan to reduce restraints in the future? - The Trust has a Reducing restrictive intervention lead and a lead nurse for standards and safety. Plan is to review the Reducing restrictive intervention strategy, using key data set to identify key actions required.
Please provide SECLUSION information under the FOI act to the following questions: -
1.Please supply any SECLUSION reports/investigations - Nil
2.How many SECLUSIONS in 2023?
|
Seclusion Incidents 2023 |
|
294 |
3.What proportion of patients were men/women?
|
Male (Including Trans Man) |
Female (Including Trans Woman) |
Not Known |
Not Specified |
|
202 |
87 |
0 |
5 |
4.How old were they?
|
Age group |
No. Patients |
|
0-17 |
29 |
|
18-30 |
108 |
|
31-40 |
84 |
|
41-50 |
35 |
|
51-60 |
32 |
|
61-70 |
5 |
|
Not Stated |
<5* |
5.What proportion of patients were classified people of the global majority or racialised communities ("POC / BAME")?
|
Ethnicity |
No. Patients |
|
Asian or Asian British - Any other Asian background |
8 |
|
Asian or Asian British - Indian |
<5* |
|
Asian or Asian British - Pakistani |
<5* |
|
Black or Black British - African |
6 |
|
Black or Black British - Any other Black background |
<5* |
|
Black or Black British - Caribbean |
<5* |
|
Mixed - Any other mixed background |
<5* |
|
Mixed - White And Black African |
<5* |
|
Mixed - White and Black Caribbean |
6 |
|
Not Known |
14 |
|
Not Stated |
40 |
|
Other Ethnic Groups - Any other ethnic group |
13 |
|
Other Ethnic Groups - Arab |
5 |
|
Other Ethnic Groups - Chinese |
<5* |
|
White |
6 |
|
White - Any other White background |
22 |
|
White - British |
166 |
6.How many people covered by the Equality Act were secluded ? All our patients who receive treatment have characteristics protected by the Equalities Act.
7.How many SECLUSIONS were investigated outside the NHS and CCG? - Nil
8.How many patients died during or 1 month after SECLUSION and what was the cause (whether or not SECLUSION was considered the cause)? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
9.How many patients died within 6 months after SECLUSION and what was the cause (whether or not SECLUSION was considered the cause)? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
10.How many patients died by suicide within 6 months of receiving SECLUSION (whether or not SECLUSION was considered the cause)? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
11.How many patients have suffered complications during and after SECLUSION and what were those complications? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
12.Have there been any formal complaints from patients/relatives about SECLUSION? We do not have this data
13.If so, what was their concerns? N/A - see above
14.How does the Trust plan to reduce SECLUSIONS in the future? - The Trust has a Reducing restrictive intervention lead and a lead nurse for standards and safety. Plan is to review the Reducing restrictive intervention strategy (to include management of seclusion), using key data set to identify key actions required.
Please provide MEDICATION ERRORS information under the FOI act to the following questions: -
1.Please supply any MEDICATION ERRORS reports/investigations - Nil
2.How many MEDICATION ERRORS in 2023?
|
No. Of Medication Incidents 2023 |
|
660 |
3.What proportion of patients were men/women?
|
Male (Including Trans Man) |
Female (Including Trans Woman) |
Not Known |
Not Specified |
|
301 |
323 |
22 |
14 |
4.How old were they?
|
Age group |
No. Patients |
|
0-17 |
53 |
|
18-30 |
114 |
|
31-40 |
131 |
|
41-50 |
88 |
|
51-60 |
76 |
|
61-70 |
61 |
|
71 And Over |
110 |
|
Not Stated |
27 |
5.What proportion of patients were classified people of the global majority or racialised communities ("POC / BAME")?
|
Ethnicity |
No. Patients |
|
Asian or Asian British - Any other Asian background |
9 |
|
Asian or Asian British - Bangladeshi |
<5* |
|
Asian or Asian British - Indian |
<5* |
|
Black or Black British - African |
5 |
|
Black or Black British - Any other Black background |
<5* |
|
Black or Black British - Caribbean |
<5* |
|
Mixed - Any other mixed background |
7 |
|
Mixed - White and Asian |
<5* |
|
Mixed - White And Black African |
<5* |
|
Mixed - White and Black Caribbean |
<5* |
|
Not Known |
61 |
|
Not Stated |
63 |
|
Other Ethnic Groups - Any other ethnic group |
6 |
|
Other Ethnic Groups - Arab |
<5* |
|
White |
32 |
|
White - Any other White background |
39 |
|
White - British |
418 |
|
White - Irish |
<5* |
6.How many people covered by the equality act endured medication errors ? All our patients who receive treatment have characteristics protected by the Equalities Act.
7.How many MEDICATION ERRORS were investigated outside the NHS and CCG? Nil
8.How many patients died during or 1 month after MEDICATION ERRORS and what was the cause (whether or not MEDICATION ERRORS was considered the cause)? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
9.How many patients died within 6 months after MEDICATION ERRORS and what was the cause (whether or not MEDICATION ERRORS was considered the cause)? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
10.How many patients died by suicide within 6 months of receiving MEDICATION ERRORS (whether or not MEDICATION ERRORS was considered the cause)? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
11.How many patients have suffered complications during and after MEDICATION ERRORS and what were those complications? )? - Exempt under Section 12 of the Freedom of Information Act 2000** as obtaining this information would entail a manual check of individual patient records.
12.Have there been any formal complaints from patients/relatives about MEDICATION ERRORS? - We do not have this data
13.If so, what was their concerns? N/A - see above
14.How does the Trust plan to prevent MEDICATION ERRORS in the future?
The Medicines Safety Officer role will continue to develop effective processes for reviewing medicines related errors and systems, taking actions to identify learning through improvements in data from our electronic systems and to be better at proactively preventing them from reoccurring. There will also be the development and implementation of a medicines safety strategy that includes:
- The reinforcement of ensuring patients are informed, engaged and involved in shared decision making about their medicines. This includes educating them about their medicines, ensuring access to information resources, and improving digital literacy around medicines for patients who prefer to access information in this way.
- Development of an integrated Electronic Prescribing and medicines administration system. This will improve how we reconcile medicines, enhance communication of prescribed medicines, aid in the choice of medicines prescribed and reduce prescribing and administration errors. The system will also incorporate clinical decision support that will improve the way that medicines are initially prescribed. This system has been procured as part of an electronic patient record project.
- Development of an organisational approach to deploying automated and barcoding technologies that enable safer selection and administration of medicines.
- Improving our medicines safety culture through the application of safety science, systems thinking, Just culture and the application of the patient safety incident response framework within investigations. This includes consideration for environmental factors like minimising interruptions, and ensuring adequate staffing.
- Continue to participate in national and integrated care systems networks and alliances to build communication channels between medicines safety officers and expert clinical leads that bridge clinical and pharmacy services between providers. This aids sharing and learning from incidents and the development of best practice models and initiatives.
- Utilising a recent restructuring within the pharmacy team to bolster support within the organisation in medicines safety leadership. This enables teams to be invited to reflect on learning from medicines safety events and to continue to engage and look for new ways to improve safety and effectiveness. This is co-ordinated centrally so that the medicines errors are shared widely and processes and systems are developed with organisational oversight such as identifying common themes in incidents and errors and the standardising of procedures to prevent them.
- Driving continuous improvement through proactive monitoring and auditing to review, test and spread improvements in patient safety.
*Where numbers are fewer than five, these have been expressed as <5 to avoid the possibility of individuals being identified
** For further details about Section 12 please see the Information Commissioner's Office website here.
The information supplied to you continues to be protected by copyright. You are free to use it for your own purposes, including for private study and non-commercial research, and for any other purpose authorised by an exception in current copyright law. Documents (except photographs) can be also used in the UK without requiring permission for the purposes of news reporting. Any other reuse, for example commercial publication, would require the permission of the copyright holder.
RE-USE OF INFORMATION
To comply with the Re-use of Public Sector Information Regulations (2015), this information is provided to you under the Open Government Licence (OGL). This licence does not grant you any right to use the Information in a way that suggests any official status or that Sussex Partnership NHS Foundation Trust endorses you or your use of the Information. The re-use of this information indicates your acceptance of the terms and conditions as set out in the Open Government Licence.
When you use our information under the OGL, you should include the following attribution:
Sussex Partnership NHS Foundation Trust 2022, licensed under the Open Government License.
If you wish to re-use information outside of the licence terms then please inform the Trust, as unauthorised re-use may be in breach of copyright law. For information where the copyright is owned by another person or organisation, you must apply to the copyright owner to obtain their permission to re-use.
FURTHER QUERIES
Should you have any general questions, please don’t hesitate to contact me directly by email at FOI@spft.nhs.uk.
If you are unhappy with the way in which your request has been handled, the Trust has an internal review procedure through which you can raise any concerns you might have. A request for an internal review should be submitted in writing to the FOI Team at the above address or by email to FOI@spft.nhs.uk.
If you are dissatisfied with the outcome of the internal review procedure, you can appeal to the Information Commissioner, who will consider whether the Trust has complied with its obligations under the Act, and can require the Trust to remedy any problems.
You can find out more about how to do this, and about the Act in general, on the Information Commissioner’s website at: www.ico.org.uk.
Complaints to the Information Commissioner should be sent to:
First Contact Team
Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Sussex Partnership NHS Foundation Trust is dedicated to looking after all personal data. Information on how the Trust collects, uses and shares this information is available on our privacy notice here.
Please remember to quote our FOI reference number which can be found at the top of this letter in any future correspondence.
I do hope you find the information provided helpful.
Regards
Liz Hecker
Liz Hecker
Freedom of Information (FOI) Officer
Information Governance Team
Sussex Partnership NHS Foundation Trust